Teslamed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
- Revenue Growth -19.12%
- Profit Growth -1581.12%
- Ebitda -484.99%
- Net Worth -189.91%
- Total Assets 21.55%
About Teslamed Pharmaceuticals
Teslamed Pharmaceuticals Private Limited (TPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 October 2019 (Five years and three months 23 days old ). Its registered office is in Ernakulam, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.50 M.
Anoop , Gopalan , and Shinoj Kunhikrishnannair serve as directors at the Company.
Company Details
-
Location
Ernakulam, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100KL2019PTC059938
-
Company No.
059938
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Oct 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Teslamed Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anoop
|
Director | 11-Oct-2019 | Current |
|
Gopalan
|
Director | 11-Oct-2019 | Current |
|
Shinoj Kunhikrishnannair
|
Director | 11-Oct-2019 | Current |
Financial Performance of Teslamed Pharmaceuticals.
Teslamed Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 19.12% decrease. The company also saw a substantial fall in profitability, with a 1581.12% decrease in profit. The company's net worth observed a substantial decline by a decrease of 189.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Teslamed Pharmaceuticals?
In 2021, Teslamed Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Aug 2020 | Others | ₹1.50 M | Open |
How Many Employees Work at Teslamed Pharmaceuticals?
Unlock and access historical data on people associated with Teslamed Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Teslamed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Teslamed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.